Search

Your search keyword '"Thouvenin, Jonathan"' showing total 19 results
Start Over Author "Thouvenin, Jonathan"
19 results on '"Thouvenin, Jonathan"'

1. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance

Author

Vokshi, Bujamin H., Davidson, Guillaume, Tawanaie Pour Sedehi, Nassim, Helleux, Alexandra, Rippinger, Marc, Haller, Alexandre R., Gantzer, Justine, Thouvenin, Jonathan, Baltzinger, Philippe, Bouarich, Rachida, Manriquez, Valeria, Zaidi, Sakina, Rao, Priya, Msaouel, Pavlos, Su, Xiaoping, Lang, Hervé, Tricard, Thibault, Lindner, Véronique, Surdez, Didier, Kurtz, Jean-Emmanuel, Bourdeaut, Franck, Tannir, Nizar M., Davidson, Irwin, and Malouf, Gabriel G.

Published
2023
Full Text
View/download PDF

2. V04-12 LEVEL 2 VENA CAVA THROMBECTOMY AND ROBOT ASSISTED RADICAL NEPHRECTOMY FOLLOWING IMMUNOTHERAPY

Author

Margue, Gaëlle, primary, Moinard-Butot, Fabien, additional, Thouvenin, Jonathan, additional, Sionneau, Baptiste, additional, Khaddad, Abderrahmane, additional, Gross-Goupil, Marine, additional, Ravaud, Alain, additional, Bladou, Franck, additional, Robert, Grégoire, additional, Barthelemy, Philippe, additional, France, Strasbourg, additional, and Bernhard, Jean-Christophe, additional

Published
2024
Full Text
View/download PDF

5. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance

Author

Vokshi, Bujamin H, Davidson, Guillaume; https://orcid.org/0000-0001-9272-3924, Tawanaie Pour Sedehi, Nassim, Helleux, Alexandra; https://orcid.org/0000-0002-3499-6227, Rippinger, Marc, Haller, Alexandre R, Gantzer, Justine, Thouvenin, Jonathan, Baltzinger, Philippe, Bouarich, Rachida, Manriquez, Valeria, Zaidi, Sakina; https://orcid.org/0000-0001-9128-0287, Rao, Priya, Msaouel, Pavlos; https://orcid.org/0000-0001-6505-8308, Su, Xiaoping, Lang, Hervé, Tricard, Thibault, Lindner, Véronique, Surdez, Didier; https://orcid.org/0000-0002-7118-7859, Kurtz, Jean-Emmanuel, Bourdeaut, Franck; https://orcid.org/0000-0001-9489-6781, Tannir, Nizar M, Davidson, Irwin; https://orcid.org/0000-0001-5533-1171, Malouf, Gabriel G; https://orcid.org/0000-0003-3527-0417, Vokshi, Bujamin H, Davidson, Guillaume; https://orcid.org/0000-0001-9272-3924, Tawanaie Pour Sedehi, Nassim, Helleux, Alexandra; https://orcid.org/0000-0002-3499-6227, Rippinger, Marc, Haller, Alexandre R, Gantzer, Justine, Thouvenin, Jonathan, Baltzinger, Philippe, Bouarich, Rachida, Manriquez, Valeria, Zaidi, Sakina; https://orcid.org/0000-0001-9128-0287, Rao, Priya, Msaouel, Pavlos; https://orcid.org/0000-0001-6505-8308, Su, Xiaoping, Lang, Hervé, Tricard, Thibault, Lindner, Véronique, Surdez, Didier; https://orcid.org/0000-0002-7118-7859, Kurtz, Jean-Emmanuel, Bourdeaut, Franck; https://orcid.org/0000-0001-9489-6781, Tannir, Nizar M, Davidson, Irwin; https://orcid.org/0000-0001-5533-1171, and Malouf, Gabriel G; https://orcid.org/0000-0003-3527-0417

Abstract

Renal medullary carcinoma (RMC) is an aggressive tumour driven by bi-allelic loss of SMARCB1 and tightly associated with sickle cell trait. However, the cell-of-origin and oncogenic mechanism remain poorly understood. Using single-cell sequencing of human RMC, we defined transformation of thick ascending limb (TAL) cells into an epithelial-mesenchymal gradient of RMC cells associated with loss of renal epithelial transcription factors TFCP2L1, HOXB9 and MITF and gain of MYC and NFE2L2-associated oncogenic and ferroptosis resistance programs. We describe the molecular basis for this transcriptional switch that is reversed by SMARCB1 re-expression repressing the oncogenic and ferroptosis resistance programs leading to ferroptotic cell death. Ferroptosis resistance links TAL cell survival with the high extracellular medullar iron concentrations associated with sickle cell trait, an environment propitious to the mutagenic events associated with RMC development. This unique environment may explain why RMC is the only SMARCB1-deficient tumour arising from epithelial cells, differentiating RMC from rhabdoid tumours arising from neural crest cells.

Published
2023

7. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas

Author

Alhalabi, Omar, primary, Thouvenin, Jonathan, additional, Négrier, Sylvie, additional, Vano, Yann-Alexandre, additional, Campedel, Luca, additional, Hasanov, Elshad, additional, Bakouny, Ziad, additional, Hahn, Andrew W, additional, Bilen, Mehmet Asim, additional, Msaouel, Pavlos, additional, Choueiri, Toni K, additional, Viswanathan, Srinivas R, additional, Sircar, Kanishka, additional, Albiges, Laurence, additional, Malouf, Gabriel G, additional, and Tannir, Nizar M, additional

Published
2023
Full Text
View/download PDF

8. Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Author

Masson, Claire, Thouvenin, Jonathan, Boudier, Philippe, Maillet, Denis, Kuchler-Bopp, Sabine, Barthélémy, Philippe, and Massfelder, Thierry

Subjects
*RENAL cell carcinoma, *IMMUNE checkpoint inhibitors, *ANTINEOPLASTIC agents, *PROTEIN-tyrosine kinase inhibitors, *TUMOR markers, *PREDICTION models, *CELL lines, *IMMUNOTHERAPY, *DRUG resistance in cancer cells
Abstract

Simple Summary: A several immunotherapy-based combinations regimen improved overall survival, and became the new first-line standard of care for metastatic clear cell renal cell carcinoma (mccRCC) patients. However, a subset of patients, approximatively 30 to 60%, are refractory to these therapies or develop a secondary acquired resistance. Currently no validated biomarkers are available in routine practice to adapt treatment strategies. Here, we summarize the potential biological biomarkers for immune checkpoint inhibitors that may have arisen from the studies of immune checkpoints. Renal cell carcinoma (RCC) represents around 2% of cancer-related deaths worldwide per year. RCC is an immunogenic malignancy, and treatment of metastatic RCC (mRCC) has greatly improved since the advent of the new immunotherapy agents, including immune checkpoint inhibitors (ICIs). However, it should be stressed that a large proportion of patients does not respond to these therapies. There is thus an urgent need to identify predictive biomarkers of efficacy or resistance associated with ICIs or ICI/Tyrosine kinase inhibitor (TKI) combinations; this is a major challenge to achieve precision medicine for mRCC in routine practice. To identify potential biomarkers, it is necessary to improve our knowledge on the biology of immune checkpoints. A lot of efforts have been made over the last decade in the field of immuno-oncology. We summarize here the main data obtained in this field when considering mRCC. As for clinical biomarkers, clinician and scientific experts of the domain are facing difficulties in identifying such molecular entities, probably due to the complexity of immuno-oncology and the constant adaptation of tumor cells to their changing environment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas

Author

Thouvenin, Jonathan, primary, Alhalabi, Omar, additional, Carlo, Maria, additional, Carril-Ajuria, Lucia, additional, Hirsch, Laure, additional, Martinez-Chanza, Nieves, additional, Négrier, Sylvie, additional, Campedel, Luca, additional, Martini, Dylan, additional, Borchiellini, Delphine, additional, Chahoud, Jad, additional, Lodi, Massimo, additional, Barthélémy, Philippe, additional, Hasanov, Elshad, additional, Hahn, Andrew W, additional, Gil, Thierry, additional, Viswanathan, Srinivas R, additional, Bakouny, Ziad, additional, Msaouel, Pavlos, additional, Asim Bilen, Mehmet, additional, Choueiri, Toni K, additional, Albiges, Laurence, additional, Tannir, Nizar M, additional, and Malouf, Gabriel G, additional

Published
2022
Full Text
View/download PDF

10. Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study

Author

Guillaume, Zoé, primary, Colomba, Emeline, additional, Thouvenin, Jonathan, additional, Saldana, Carolina, additional, Campedel, Luca, additional, Dumont, Clément, additional, Laguerre, Brigitte, additional, Maillet, Denis, additional, Vicier, Cécile, additional, Rolland, Frédéric, additional, Borchiellini, Delphine, additional, Barthelemy, Philippe, additional, Albiges, Laurence, additional, Auclin, Edouard, additional, Roulleaux Dugage, Matthieu, additional, Oudard, Stéphane, additional, and Thibault, Constance, additional

Published
2022
Full Text
View/download PDF

11. Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.

Author

Alhalabi, Omar, primary, Thouvenin, Jonathan, additional, Negrier, Sylvie, additional, Vano, Yann-Alexandre, additional, Campedel, Luca, additional, Hasanov, Elshad, additional, Bakouny, Ziad, additional, Hahn, Andrew Warren, additional, Bilen, Mehmet Asim, additional, Choueiri, Toni K., additional, Viswanathan, Srinivas Raghavan, additional, Sircar, Kanishka, additional, Albiges, Laurence, additional, Malouf, Gabriel, additional, and Tannir, Nizar M., additional

Published
2022
Full Text
View/download PDF

12. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance

Author

Vokshi, Bujamin, primary, Davidson, Guillaume, additional, Helleux, Alexandra, additional, Rippinger, Marc, additional, Haller, Alexandre, additional, Gantzer, Justine, additional, Baltzinger, Philippe, additional, Thouvenin, Jonathan, additional, Bouarich-Bourimi, Rachida, additional, Manriquez, Valentina, additional, Zaidi, Sakina, additional, Msaouel, Pavlos, additional, Su, Xiaoping, additional, Lang, Hervé, additional, Tricard, Thibault, additional, Lindner, Véronique, additional, Surdez, Didier, additional, Kurtz, Jean-Emmanuel, additional, BOURDEAUT, Franck, additional, Tannir, Nizar, additional, Davidson, Irwin, additional, and Malouf, Gabriel, additional

Published
2022
Full Text
View/download PDF

13. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma

Author

Hirsch, Laure, primary, Martinez Chanza, Nieves, additional, Farah, Subrina, additional, Xie, Wanling, additional, Flippot, Ronan, additional, Braun, David A., additional, Rathi, Nityam, additional, Thouvenin, Jonathan, additional, Collier, Katharine A., additional, Seront, Emmanuel, additional, de Velasco, Guillermo, additional, Dzimitrowicz, Hannah, additional, Beuselinck, Benoit, additional, Xu, Wenxin, additional, Bowman, I. Alex, additional, Lam, Elaine T., additional, Abuqayas, Bashar, additional, Bilen, Mehmet Asim, additional, Varkaris, Andreas, additional, Zakharia, Yousef, additional, Harrison, Michael R., additional, Mortazavi, Amir, additional, Barthélémy, Philippe, additional, Agarwal, Neeraj, additional, McKay, Rana R., additional, Brastianos, Priscilla K., additional, Krajewski, Katherine M., additional, Albigès, Laurence, additional, Harshman, Lauren C., additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

14. Integrative genomics uncover mechanisms of renal medullary carcinoma transformation, microenvironment landscape and therapeutic vulnerabilities

Author

Vokshi, Bujamin H., primary, Davidson, Guillaume, additional, Helleux, Alexandra, additional, Rippinger, Marc, additional, Haller, Alexandre R., additional, Gantzer, Justine, additional, Thouvenin, Jonathan, additional, Baltzinger, Philippe, additional, Bouarich, Rachida, additional, Manriquez, Valeria, additional, Zaidi, Sakina, additional, Msaouel, Pavlos, additional, Su, Xiaoping, additional, Lang, Hervé, additional, Tricard, Thibault, additional, Lindner, Véronique, additional, Surdez, Didier, additional, Kurtz, Jean-Emmanuel, additional, Bourdeaut, Franck, additional, Tannir, Nizar M., additional, Davidson, Irwin, additional, and Malouf, Gabriel G., additional

Published
2021
Full Text
View/download PDF

16. Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).

Author

Thouvenin, Jonathan, primary, Alhalabi, Omar, additional, Hirsch, Laure, additional, Hasanov, Elshad, additional, Barthelemy, Philippe, additional, Martini, Dylan J., additional, Campedel, Lucas, additional, Amrane, Karim, additional, Borchiellini, Delphine, additional, Chahoud, Jad, additional, Bakouny, Ziad, additional, Ravi, Praful, additional, Viswanathan, Srinivas Raghavan, additional, Bilen, Mehmet Asim, additional, Choueiri, Toni K., additional, Tannir, Nizar M., additional, and Malouf, Gabriel G., additional

Published
2021
Full Text
View/download PDF

18. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.

Author

Debien, Véronique, Thouvenin, Jonathan, Lindner, Véronique, Barthélémy, Philippe, Lang, Hervé, Flippot, Ronan, and Malouf, Gabriel G.

Subjects
*ANTINEOPLASTIC agents, *GENETIC mutation, *RENAL cell carcinoma, *SARCOMA, *T cells, *PHARMACODYNAMICS
Abstract

Sarcomatoid features in renal cell carcinoma (RCC) have long been associated with dismal prognosis and poor response to therapy, while biological mechanisms underpinning sarcomatoid dedifferentiation remained obscure. Several efforts have been conducted to break down the molecular profile of sarcomatoid RCC and investigate different targeted therapeutic approaches. Mutations enriched for in sarcomatoid RCC involve, notably, TP53, BAP1, cell cycle, and chromatin-remodeling genes. The immunological landscape of these tumors is also gradually being uncovered, showing frequent expression of programmed cell death ligand-1 (PD-L1) and high levels of tumor-infiltrating lymphocytes. These features may be major determinants for the activity of immune checkpoint inhibitors in this population, which has been confirmed by retrospective studies and subgroup analyses of large randomized phase 3 trials. Combinations based on PD-1/PD-L1 inhibition have demonstrated response rates and complete responses in >50% and >10% of patients in the first-line metastatic setting, respectively, with median overall survival exceeding two years. This remarkable improvement in outcomes effectively establishes immune checkpoint inhibitor combinations as a new standard of care in patients with sarcomatoid RCC. New research fields, including epigenetic regulations and tumor–microenvironment interactions, may further sharpen understanding of sarcomatoid RCC and advance therapeutic developments. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

19. [Non-clear cell renal cell carcinoma: clinico-biological characteristics and therapeutic management except surgery].

Author

Thouvenin J, Barthélémy P, and Ladoire S

Subjects
Humans, Kidney Neoplasms diagnosis, Kidney Neoplasms drug therapy
Abstract

Non-clear cell renal cell carcinomas (nccRCC) account for nearly 25% of all kidney cancers, and represent a group of highly heterogeneous tumors both in terms of histological varieties and also oncogenic biological abnormalities. The clinical presentation as well as the prognosis of the patients is also very variable. Given the rarity of each tumor entity, there are very few clinical trials that have focused on a well-defined variety of non-clear cell cancer. So, it is difficult to interpret these studies, and therefore to develop clear recommendations for medical management of advanced disease. In this article, the main clinico-biological characteristics, as well as a summary of the clinical results obtained in patients with nccRCC cancer, except surgery, will be presented., (Copyright © 2020 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results